TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01331993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO (Patheon)
Description: VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO (Patheon)
Description: VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO (Patheon)
Description: VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO (Patheon)
Description: VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marketed enteric-coated naproxen formulation
Description: Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marketed enteric-coated naproxen formulation
Description: Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marketed enteric-coated naproxen formulation
Description: Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marketed enteric-coated naproxen formulation
Description: Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marketed enteric-coated naproxen formulation
Description: Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marketed enteric-coated naproxen formulation
Description: Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet
Study: NCT01092325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXL-1020
Description: Intravenous infusion of one of 3 active dosages of CXL-1020 at dosages higher than in Cohort 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for CXL-1020 Cohort 1
Description: A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for CXL-1020 Cohort 2
Description: A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
Study: NCT04519073

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: V-306 candidate vaccine
Description: Each V-306 monomer consists of the following elements:~1. A Lipopeptide Building Block that contains an optimized, artificially designed coiled-coil domain, which self-assembles into highly stable trimers.~2. A 'universal' T-helper epitope fused at the C-terminus of the coiled-coil domain.~3. A lipid component di-palmitoyl-S-glyceryl cysteine (Pam2C), fused at the N-terminus.~4. A mimetic of the Palivizumab epitope, referred to RSV F-protein site II antigen mimetic (FsIIm), which is coupled near the C-terminus of the Lipopeptide Building Block via a short maleimide-PEG-oxime linker.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V-306 candidate vaccine
Description: Each V-306 monomer consists of the following elements:~1. A Lipopeptide Building Block that contains an optimized, artificially designed coiled-coil domain, which self-assembles into highly stable trimers.~2. A 'universal' T-helper epitope fused at the C-terminus of the coiled-coil domain.~3. A lipid component di-palmitoyl-S-glyceryl cysteine (Pam2C), fused at the N-terminus.~4. A mimetic of the Palivizumab epitope, referred to RSV F-protein site II antigen mimetic (FsIIm), which is coupled near the C-terminus of the Lipopeptide Building Block via a short maleimide-PEG-oxime linker.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V-306 candidate vaccine
Description: Each V-306 monomer consists of the following elements:~1. A Lipopeptide Building Block that contains an optimized, artificially designed coiled-coil domain, which self-assembles into highly stable trimers.~2. A 'universal' T-helper epitope fused at the C-terminus of the coiled-coil domain.~3. A lipid component di-palmitoyl-S-glyceryl cysteine (Pam2C), fused at the N-terminus.~4. A mimetic of the Palivizumab epitope, referred to RSV F-protein site II antigen mimetic (FsIIm), which is coupled near the C-terminus of the Lipopeptide Building Block via a short maleimide-PEG-oxime linker.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V-306 candidate vaccine
Description: Each V-306 monomer consists of the following elements:~1. A Lipopeptide Building Block that contains an optimized, artificially designed coiled-coil domain, which self-assembles into highly stable trimers.~2. A 'universal' T-helper epitope fused at the C-terminus of the coiled-coil domain.~3. A lipid component di-palmitoyl-S-glyceryl cysteine (Pam2C), fused at the N-terminus.~4. A mimetic of the Palivizumab epitope, referred to RSV F-protein site II antigen mimetic (FsIIm), which is coupled near the C-terminus of the Lipopeptide Building Block via a short maleimide-PEG-oxime linker.
Study: NCT03296501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients
Description: 3 injections of ADRC: 1 intraspinal and 2 intrathecal
Study: NCT00490841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Herculink Elite Renal Stent System
Description: This is a prospective, non-randomized, single arm, multi-center study to evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in patients with sub-optimal renal PTA results in de novo or restenotic renal artery lesions. Patients who satisfy the inclusion/exclusion criteria will be enrolled at sites in the United States. Patients will have follow up visits for evaluation.
Study: NCT05237323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil 2 g per day
Description: mycophenolate mofetil 2 g per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine of 150 [75; 150] mg per day
Description: azathioprine at an average dose of 150 \[75; 150\] mg per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.
Study: NCT02289703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg
Description: Single oral dose of rivaroxaban 15-mg tablet on Day 1 of each of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg
Description: Single oral dose of rivaroxaban 15-mg tablet on Day 1 of each of the treatment periods.
Study: NCT01236443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: 3 mg/m2 IV
Study: NCT03051542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/￼￼￼￼dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
Study: NCT01188694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychotherapy plus Methylene Blue, USP
Description: This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, 260 mg of methylene blue, USP will be given.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychotherapy plus Placebo
Description: This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, capsules containing the placebo will be given.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed Psychotherapy
Description: Individuals must wait approximately five to six weeks to start treatment. They will come in for two check-in appointments before starting treatment. Treatment will consist of ten twice-weekly psychotherapy sessions (90-120 min each session).
Study: NCT03893552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative expiratory pressure
Description: Using a cough assist, a negative expiratory pressure will be applied while recording the respiratory flow in patients suffering from sleeping disorders or snoring.
Study: NCT02016625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir
Study: NCT01092325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CXL-1020 Dose for Echo Cohort A
Description: A 4 hour fixed dose of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CXL-1020 Doses for Echo Cohort B
Description: A 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect followed by another higher 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
Study: NCT04518397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theatre
Description: 6-week participatory arts culturally-informed theatre program
Study: NCT00430586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A, free of complexing proteins
Description: Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A, free of complexing proteins
Description: Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
Study: NCT02016625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study: NCT00593307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high GI
Description: high GI and high carb breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI
Description: low GI, high carb breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI Low Carb
Description: low GI low carb breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI Low carb
Description: high GI low carb breakfast
Study: NCT00685243

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser treatment
Description: Fraxel and pulsed dye laser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser treatment
Description: Fraxel and pulsed dye laser
Study: NCT03160833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-453
Description: oral administrative
Study: NCT03459664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RECOVER
Description: For each patient baseline assessment and individual support by a diagnostic and crisis resolution home treatment team is available. In addition, patients will be treated with specific interventions based on their severity grade:~Grade 1 (mild): social support, information about mental disorder, e-therapy, consultation, self help, peer-support, supported employment.~Grade 2 (medium): psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 3 (medium to severe): case management, psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 4 (severe): assertive community treatment, psychotherapy, medical treatment, e-therapy, peer-support, supported employment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: For each patient all common care options within the German health care system are available, depending on the severity grade 1 to 4.~This includes the following options: hospital based in-patient, out-patient treatment and day care, community based health care services, general practitioners, private psychiatrists and psychotherapists, self help.
Study: NCT00830973

Intervention type: OTHER
Intervention: Poor Metabolism Status Follow Up Therapy Considerations
Description: If the patient's CYP2D6 metabolism status is 'poor' then specialist pharmacist will discuss drug therapy alternatives to tamoxifen.

Intervention type: OTHER
Intervention: CYP2D6 Inhibiting Drugs
Description: If the patient after having a CYP2D6 test has any drugs that inhibit tamoxifen metabolism then specialist pharmacist will contact the physician for alternative drug therapies.
Study: NCT03209843

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous recanalization of chronic total occlusion
Description: Percutaneous recanalization of chronic total occlusion followed by immediate systematic coronary optical frequency domain imaging (OFDI) at inclusion. Intra-individual post stenting assessment of reendothelialization with a second coronary angiography with OFDI analysis at 3 months.
Study: NCT01289483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fospropofol
Description: After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fospropofol
Description: After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fospropofol
Description: After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fospropofol
Description: After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
Study: NCT02819284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121 0.25% Ophthalmic Suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of KPI-121 0.25% Ophthalmic Suspension
Study: NCT03345693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MoTrack Therapy
Description: A software that runs on a tablet or computer that reads information from a Universal Serial Bus external sensor and instructs patients in their exercises, giving patients feedback as necessary, and recording patient progress and activity.
Study: NCT04695769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin
Description: Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir with weight-based Ribavirin for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]
Description: Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir for 12 weeks.
Study: NCT03057821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3% hydrogen peroxide
Description: The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
Study: NCT02717455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.~STRATUM 2: Non-progressed DIPG or H3K27M+ Thalamic DMG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.~STRATUM 2: Non-progressed DIPG or H3K27M+ Thalamic DMG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria.
Study: NCT03610230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside
Description: Iron Isomaltoside 1000 (Monofer®) consists of iron with a tighter binding to its carbohydrate moiety with less free iron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Isomaltoside
Description: Iron Isomaltoside 1000 (Monofer®) consists of iron with a tighter binding to its carbohydrate moiety with less free iron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Description: the currently most widely used intravenous iron preparation with good safety profile

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: the currently most widely used intravenous iron preparation with good safety profile
Study: NCT04142086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine
Description: Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
Study: NCT03135041

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber-containing dietary supplement
Description: Effects of fiber-containing dietary supplement on weight loss during energy restriction
Study: NCT04142086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine
Description: Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine
Description: Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine
Description: Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
Study: NCT03135041

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Effects of placebo supplement on weight loss during energy restriction
Study: NCT03873987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current Formulation of Oritavancin
Description: Current formulation of oritavancin (3 hour infusion of 1200 mg in 1000 ml of D5W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kimyrsa
Description: New formulation of oritavancin (1 hour infusion of 1200 mg in 250 ml of saline)
Study: NCT01199211

Intervention type: OTHER
Intervention: Exercise training, women, marathon
Description: Prospective study with no intervention in women who have volunteered to run a full marathon or a half-marathon. Each subject will serve as own control. Each subject will be studies at 3 stages: baseline, after at least 12 weeks of training for the marathon (we will not provide training), 6 weeks after running the marathon.
Study: NCT00762398

Intervention type: DEVICE
Intervention: Masimo hemoglobin-meter
Description: Placing a probe on the finger

Intervention type: BIOLOGICAL
Intervention: drawing blood sample
Description: drawing a blood sample less that 0.5 mL each time, for around 10-12 times along the surgery (depends on surgical time)
Study: NCT02706444

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balloon angioplasty
Description: After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in \> 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-coated Balloon angioplasty
Description: After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in \> 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
Study: NCT01824381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Place amniotic membrane in large wounds
Description: After the process of obtaining the amniotic membrane, it must be processed, frozen and thawed.~The wound is washed with saline and, if necessary it will be debrided. We will take microbiological control cultures. Then apply the amniotic membrane fragments sufficient to cover the wound by contacting the basal membrane of the amniotic membrane with granulation tissue.~We will place a new membrane weekly to a maximum of 6 times.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Obtaining and Cryopreservation of amniotic membrane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amniotic membrane